Usually, cardiogenic shock patients are on hemodynamic support at that point, usually with a variety of vasopressor agents. Then we would go ahead and put in a balloon pump. We probably ...

According to the results of the SHOCK trial, ERV is now a class I indication for this patient population in the ACC/AHA myocardical infarction guidelines. [22] Mortality with CABG was similar to ...

Two heart pump systems were approved for the treatment of acute decompensated HF and cardiogenic shock in certain pediatric patients. Real-world data are needed to support on-label use.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock.

most indicated they would prioritize istaroxime before using other existing classes of therapies such as inotropes and ...

The filing builds on encouraging results from preclinical animal studies and clinical trials in acute heart failure (AHF) and early cardiogenic ... shock and AHF including inotropes and ...

Steve Simonson, CMO and SVP of Windtree. "We believe this characteristic may be related to SERCA2a activation by istaroxime and it has the potential to differentiate istaroxime from current drug ...